Bharat Biotech has its manufacturing facility situated atGenome Valley,Hyderabad, India.[5] As of July 2020, the company has over 700 employees[6] and has a presence worldwide.[5]
The company has been responsible for developing an eco-friendly recombinant[7] and a naturally attenuated strain derivedRotavirus vaccine called ROTAVAC.[8][9] They were one of the first to develop vaccines for viral diseases likeChikungunya[10][11] andZika.[12][13] The company also produces vaccines forJapanese Encephalitis,[14] influenza H1N1, Rabies.[15] Bharat Biotech hasbiosafety level 3 (BSL3) laboratories.[16]
Bharat Biotech has delivered over nine billion doses of vaccines globally as of May 2025, has over 145 globalpatents and a portfolio of over 19 vaccines, fourbiotherapeutics and registrations in over 125 countries.[15]
In April 2020, the company announced that they have partnered with US-based company FluGen andUniversity of Wisconsin-Madison to develop a COVID-19 vaccine.[17][18]
A 5ml vial of Covaxin
In May 2020, Indian Council of Medical Research's (ICMR's)National Institute of Virology approved and provided the virus strains for developing a fully indigenousCOVID-19 vaccine.[19][20] On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2clinical trials in India for a developmentalCOVID-19 vaccine namedCovaxin, from the Drugs Controller General of India (DCGI),Government of India.[21][22][23][24] The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[25] A total of 12 sites were selected by theIndian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[26][27]
In September 2020, the company announced that it was going to manufacture the novelchimp-adenovirus, a single doseintranasal vaccine (codenamedBBV154) forCOVID-19 being developed in collaboration with the American company Precision virologics[28] andWashington University School of Medicine inSt. Louis, Missouri. It is currently undergoing clinical trials.[29][30] On October 12, 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age.[31]
In March 2021,Reuters reported that Chinese state-backed cyber-espionage groupRed Apollo targeted Bharat Biotech's intellectual property forexfiltration.[32]
On May 21, 2025, Bharat Biotech successfully completed Phase III clinical trials of its oral cholera vaccine, Hillchol, demonstrating efficacy against both Ogawa and Inabaserotypes.[15] The findings of the study have been published in theScienceDirect vaccine journal.[15]
₹8,148 crore (US$960 million) (FY22)[3]
